C
Christina Perry
Researcher at University of Nottingham
Publications - 19
Citations - 611
Christina Perry is an academic researcher from University of Nottingham. The author has contributed to research in topics: DNA repair & Base excision repair. The author has an hindex of 13, co-authored 19 publications receiving 525 citations.
Papers
More filters
Journal ArticleDOI
Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
Rebeka Sultana,Tarek Mohamed Ahmed Abdel-Fatah,Christina Perry,Paul M. Moseley,Nada Albarakti,Vivek Mohan,Claire Seedhouse,Stephen Chan,Srinivasan Madhusudan +8 more
TL;DR: Evidence is provided that ATR inhibition is suitable for synthetic lethality application and cisplatin chemopotentiation in XRCC1 deficient ovarian cancer cells.
Journal ArticleDOI
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
Tarek M. A. Abdel-Fatah,Christina Perry,P. D. Dickinson,Graham Ball,Paul M. Moseley,Srinivasan Madhusudan,Ian O. Ellis,Stephen Chan +7 more
TL;DR: Adding Bcl2 to the panel of markers used in current clinical practice could provide both prognostic and predictive information in TNBC, whereas TNBC/Bcl2+ TNBC seems to be resistant to ATC-CT and may benefit from a trial of different type of chemotherapy with/without novel-targeted agents.
Journal ArticleDOI
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
Tarek M. A. Abdel-Fatah,Fiona K. Middleton,Arvind Arora,Devika Agarwal,Tao Chen,Paul M. Moseley,Christina Perry,Rachel Doherty,Stephen Chan,Andrew R. Green,Emad A. Rakha,Graham Ball,Ian O. Ellis,Nicola J. Curtin,Srinivasan Madhusudan +14 more
TL;DR: Evidence is provided that ATR and CHEK1 are promising biomarkers and rational drug targets for personalized therapy in breast cancer and remain an independent predictor of adverse outcome.
Journal ArticleDOI
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Nada Albarakati,Tarek M. A. Abdel-Fatah,Rachel Doherty,Roslin Russell,Devika Agarwal,Paul M. Moseley,Christina Perry,Arvind Arora,Nouf Alsubhi,Claire Seedhouse,Emad A. Rakha,Andrew R. Green,Graham Ball,Stephen Chan,Carlos Caldas,Ian O. Ellis,Srinivasan Madhusudan +16 more
TL;DR: XRCC1 and pol β expression status in BRCA1 negative tumours may have prognostic significance and be targeted by ATM or DNA‐PKcs inhibitors for personalized therapy.
Journal ArticleDOI
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
Tarek M. A. Abdel-Fatah,Arvind Arora,Paul M. Moseley,Clare Coveney,Christina Perry,Kerstie Johnson,Christopher Kent,Graham Ball,Stephen Chan,Srinivasan Madhusudan +9 more
TL;DR: Evidence is provided that ATM, ATR and DNA-PKcs involved in DDR are not only promising biomarkers but are also rational targets for personalized therapy in ovarian cancer.